Dabigatrán Suspension and Restart Guidelines

Introduction to Dabigatrán Management

The American College of Chest Physicians recommends that dabigatrán can be suspended up to 72 hours after low-risk hemorrhagic procedures and up to 96 hours after high-risk hemorrhagic procedures without the need for overlap with heparin, due to its rapid onset of action 1, 2

For patients with a creatinine clearance (CrCl) ≥50 mL/min, dabigatrán can be suspended for up to 72 hours before restarting, according to the American College of Chest Physicians guidelines 1, 2
For patients with a CrCl <50 mL/min, dabigatrán can be suspended for up to 96 hours before restarting, as recommended by the American College of Chest Physicians 1, 2
The risk of thromboembolism in the patient also plays a role, with high-risk patients requiring earlier restart of dabigatrán, as suggested by the Blood journal 2, 4

For low-to-moderate risk hemorrhagic procedures, dabigatrán can be restarted at least 24 hours after the procedure without the need for heparin overlap, as recommended by the American College of Chest Physicians 1, 2
For high-risk hemorrhagic procedures, dabigatrán should be restarted between 48-72 hours after the procedure, with no need for heparin overlap if restarted within 96 hours, according to the American College of Chest Physicians guidelines 1, 2

The rapid onset of action of dabigatrán makes it unnecessary to overlap with heparin when restarting within the recommended times, as stated by the American College of Chest Physicians 1, 2
The quick appearance and disappearance of the anticoagulant effect of direct oral anticoagulants (DOACs) eliminates the need for bridging therapy with short-acting anticoagulants like unfractionated heparin or low molecular weight heparin, as recommended by the American College of Chest Physicians 1, 2

Careful evaluation of hemostasis is necessary before restarting dabigatrán, as suggested by the Blood journal and the American College of Chest Physicians 2, 4
Restarting dabigatrán too soon after high-risk hemorrhagic procedures should be avoided, as warned by the Blood journal and the American College of Chest Physicians 2, 4
Unnecessary use of heparin overlap when restarting dabigatrán within the recommended period should be avoided, as recommended by the American College of Chest Physicians 1, 2